This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log in
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Jul;44(7):1855-9.
doi: 10.1128/AAC.44.7.1855-1859.2000.

A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever

Affiliations
Clinical Trial

A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever

N T Chinh et al. Antimicrob Agents Chemother. 2000 Jul.

Abstract

To examine the efficacy and safety of short courses of azithromycin and ofloxacin for treating multidrug-resistant (MDR, i.e., resistant to chloramphenicol, ampicillin, and cotrimoxazole) and nalidixic acid-resistant enteric fever, azithromycin (1 g once daily for 5 days at 20 mg/kg/day) and ofloxacin (200 mg orally twice a day for 5 days at 8 mg/kg/day) were compared in an open randomized study in adults admitted to a hospital with uncomplicated enteric fever. A total of 88 blood culture-confirmed patients were enrolled in the study (86 with Salmonella enterica serovar Typhi and 2 with S. enterica serovar Paratyphi A). Of these, 44 received azithromycin and 44 ofloxacin. A total of 68 of 87 (78%) isolates were MDR serovar Typhi, and 46 of 87 (53%) were nalidixic acid resistant. The MIC(90) (range) of azithromycin was 8 (4 to 16) microgram/ml for the isolates. The MIC(90) (range) of ofloxacin for the nalidixic acid-sensitive isolates was 0.03 (0.015 to 0.06) microgram/ml and for the nalidixic acid-resistant isolates it was 0.5 (0.25 to 1.0) microgram/ml. There was no significant difference in the overall clinical cure rate with ofloxacin and azithromycin (38 of 44 [86.4%] versus 42 of 44 [95.5%]; P = 0.27) or in the patients infected with nalidixic acid-resistant typhoid (17 of 21 [81.0%] versus 24 of 25 [96.0%]; P = 0.16). However, patients with nalidixic acid-resistant typhoid treated with ofloxacin had a longer fever clearance time compared with those treated with azithromycin (174 [60 to 264] versus 135 [72 to 186] h; P = 0.004) and had positive fecal cultures after the end of treatment (7 of 17 [41%] versus 0 of 19 [0%]; P = 0.002). Both antibiotics were well tolerated. A 5-day course of azithromycin was effective for the treatment of enteric fever due to MDR and nalidixic-acid-resistant serovar Typhi, whereas the ofloxacin regimen chosen was less satisfactory for these strains.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
(A) Fever clearance times for patients infected with a nalidixic acid-sensitive isolate of serovar Typhi or serovar Paratyphi A. (B) Fever clearance times for patients infected with a nalidixic acid-resistant isolate of serovar Typhi.

References

    1. Brown N M, Millar M R, Frost J A, Rowe B. Ciprofloxacin resistance in Salmonella paratyphi A. J Antimicrob Chemother. 1994;33:1258–1259. - PubMed
    1. Brown J C, Shanahan P M A, Jesudason M V, Thomson C J, Aymes S G B. Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multi-resistant Salmonella typhi in India. J Antimicrob Chemother. 1996;37:891–900. - PubMed
    1. Butler T, Girard A E. Comparative efficacies of azithromycin and ciprofloxacin against experimental Salmonella typhimurium infection in mice. J Antimicrob Chemother. 1993;31:313–319. - PubMed
    1. Butler T, Sridhar C, Daga M, Kani K, Pandit R, Khakhria R, Potkar C, Johnson R. Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India. J Antimicrob Chemother. 1999;44:243–250. - PubMed
    1. Chinh N T, Solomon T, Thong M X, Ly N T, Hoa N T T, Wain J, Diep T S, Smith M D, Day N P J, Phi L T, Parry C M, White N J. Short course of ofloxacin for the treatment of enteric fever. Trans R Soc Trop Med Hyg. 1997;91:347–349. - PubMed

Publication types

Cite

AltStyle によって変換されたページ (->オリジナル) /